Hydroxyurea Therapy for Pediatric Patients With Hemoglobin SC Disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PURPOSE: Hydroxyurea (HU) has laboratory and clinical efficacy in hemoglobin SS (HbSS) disease, but its benefits in hemoglobin SC (HbSC) disease are unknown. A recent adult HbSC disease pilot trial with HU therapy documented a modest laboratory benefit. Our goal was to evaluate the laboratory and clinical responses of selected pediatric patients with severe HbSC disease to HU therapy. PATIENTS AND METHODS: As part of a retrospective case series, patients were selected from the Duke Pediatric Sickle Cell Program based on the frequency and severity of their vasoocclusive events or an episode of acute chest syndrome. Oral HU therapy was started as a single daily dose and increased to the maximally tolerated dose based on myelosuppression. Laboratory evaluation was performed at baseline and monthly thereafter. Once the maximum tolerated dose was reached, laboratory data were monitored bimonthly. RESULTS: We treated six severely affected pediatric HbSC patients with HU for a median of 27 months. Mean corpuscular volume increased significantly (+26 fL) without change in hemoglobin concentration (-0.1 g/dL); neutrophils decreased significantly. Percentage of fetal hemoglobin (+8.5%) and percentage of F cells (+35.7%) increased significantly. Two experienced only mild and reversible toxicity. CONCLUSION: The laboratory responses in our pediatric patients with HbSC disease were striking, with increases in percentage of fetal hemoglobin and percentage of F-cells approaching responses observed in adult and pediatric patients with HbSS disease. All patients improved clinically. Our findings demonstrate that HU therapy benefits pediatric patients with severe HbSC disease, although larger clinical trials of HU therapy in HbSC disease are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 2×
“Clinically, patients administered HU therapy have significantly fewer painful and other acute vasoocclusive events (3,4).”
BackgroundA multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Bridges, K., Barabino, G., Brugnara, C., Cho, M., Christoph, G., Dover, G., Ewenstein, B., Golan, D., Guttmann, C., Hofrichter, J., et al. (1996) · Blood · doi:10.1182/blood.v88.12.4701.bloodjournal88124701 · Cited by 184 · cited 1×
“Hydroxyurea also decreases erythrocyte adhesion to endothelial cells (10,11).”
Background
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Stuart, M. J., & Nagel, R. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17192-4 · Cited by 819
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Self-citationZimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2004) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 313
Self-citationEffects of hydroxyurea treatment for patients with hemoglobin SC disease
Luchtman‐Jones, L., Pressel, S., Hilliard, L., Brown, R. C., Smith, M. G., Thompson, A. A., Lee, M. T., Rothman, J., Rogers, Z. R., Owen, W., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24255 · Cited by 86
“erated, and the short-term toxicities, consisting primarily of reversible neutropenia and thrombocytopenia, were manageable [21,22].”
BackgroundSelf-citation
Metadata
- Authors
- Miller, M. K., Zimmerman, S. A., Schultz, W. H., & Ware, R. E.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2001-06
- Volume
- 23
- Issue
- 5
- Pages
- 306-308
- ISSN
- 0192-8562 (ISSN-L)
- OpenAlex
- W1989872169
- Cited by
- 44
- References
- 2
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydroxyurea Therapy for Pediatric Patients With Hemoglobin SC Disease. https://app.cochat.ai/papers/10.1097/00043426-200106000-00014
- The paper
- Miller, M. K., Zimmerman, S. A., Schultz, W. H., & Ware, R. E. (2001). Hydroxyurea Therapy for Pediatric Patients With Hemoglobin SC Disease. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-200106000-00014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.